Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

Frequency and Causes of Mortality in Chronic Total Occlusion

In recent years, there has been an increase in the number of percutaneous coronary interventions (PCI) performed to treat chronic total occlusion (CTO). This increase is due to the availability of more advanced technology and greater experience of both operators and specialized centers. However, it is important to note that this technique is not free from complications, which tend to be slightly higher compared with other types of PCI. In some cases, the mortality rate can reach 1%.

Frecuencia y causas de mortalidad en Oclusiones Totales Crónicas

In an analysis of the PROGRESS-CTO Registry, researchers included data from 12,928 patients. Of this group, 52 (0.4%) subjects died during the hospitalization period.

The patients who lost their lives were older, had a higher number of comorbidities, had undergone myocardial revascularization surgery (MRS), and had a lower ejection fraction. 

Additionally, they obtained unfavorable results in the angiography, with a higher presence of calcification and tortuosity, and a higher score according to the CTO JAPAN Score. Retrograde recanalization was more frequently used in these cases.

The PROGRESS CTO Score for major adverse cardiovascular events (MACE), mortality, pericardiocentesis, and perforation was also higher in the patients who died.

Read also: Association Between Radial Wall Strain (RWS) and Risk of Acute Myocardial Infarction.

Procedure duration, fluoroscopy time, and radiation dose were higher in the patients who lost their lives, and so was the radiation dose they received.

The success rate of PCI was lower among patients who died (62% vs. 87%; P < 0.001).

Regarding the causes of cardiac-related mortality, in 43 patients, cardiac tamponade was the most frequent (30 cases), followed by acute myocardial infarction (9 cases) and cardiogenic shock (4 cases). Among the non-cardiac causes, there were 3 cases of stroke, 2 cases of renal failure, 2 cases of respiratory failure, and 2 cases of hemorrhagic shock.

Conclusion

In conclusion, approximately 0.4% of all patients undergoing PCI for chronic total occlusion die during hospitalization. Cardiac tamponade is identified as the main cause of death. The PROGRESS CTO Score for complications can be useful in assessing the risk in patients with chronic occlusion who will undergo PCI.

Dr. Carlos Fava - Consejo Editorial SOLACI

Dr. Carlos Fava.
Member of the Editorial Board of SOLACI.org.

Original Title: Periprocedural Mortality in Chronic Total Occlusion Percutaneous Coronary Intervention: Insights From the PROGRESS-CTO Registry.

Reference: Bahadir Simsek, et al. Circ Cardiovasc Interv. 2023;16:e012977. DOI: 10.1161/CIRCINTERVENTIONS.123.012977.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology


More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

GLUCO-TAVI | Can Glucocorticoids Reduce the Need for Permanent Pacemaker Implantation After TAVI?

Despite the expansion of transcatheter aortic valve implantation (TAVI) indications, cardiac conduction disturbances (CCD) and the need for permanent pacemaker implantation (PPI) remain the...

EuroPCR 2026 | TAVI in Women: Do Supra-Annular Valves Offer a True Hemodynamic Advantage?

Women represent a particularly challenging population for TAVI, as they often have smaller aortic annuli, greater frailty, and an increased risk of prosthesis-patient mismatch....

EuroPCR 2026 | TAVI or Surgery in Younger Patients? Quality of Life and 3-Year Outcomes from NOTION-2

The expansion of TAVI into younger and lower surgical-risk populations has sparked a new debate: beyond mortality and stroke, which strategy provides better functional...